Blockbuster bombing

Targanta Therapeutics Corp. is expected to release top-line Phase II data on Tuesday that would show its oritavancin could work as a single infusion to treat complicated skin and skin structure infections caused by Gram-positive pathogens. This would be a huge advantage over the competition, which requires once- or twice-daily infusions over 7-14 days.

President and CEO Mark Leuchtenberger told BioCentury that 70-75% of patients with Gram-positive cSSSIs are treated with vancomycin, which is given in 1-hour infusions twice daily for 10-14 days...